Valeo Pharma Management
Management criteria checks 1/4
Valeo Pharma's CEO is Steve Saviuk, appointed in Jan 2003, has a tenure of 21.25 years. total yearly compensation is CA$466.29K, comprised of 53.6% salary and 46.4% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth €14.21K. The average tenure of the management team and the board of directors is 1.7 years and 0.4 years respectively.
Key information
Steve Saviuk
Chief executive officer
CA$466.3k
Total compensation
| CEO salary percentage | 53.6% |
| CEO tenure | 21.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.7yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jan 31 2024 | n/a | n/a | -CA$28m |
| Oct 31 2023 | CA$466k | CA$250k | -CA$28m |
| Jul 31 2023 | n/a | n/a | -CA$28m |
| Apr 30 2023 | n/a | n/a | -CA$27m |
| Jan 31 2023 | n/a | n/a | -CA$26m |
| Oct 31 2022 | CA$274k | CA$240k | -CA$26m |
| Jul 31 2022 | n/a | n/a | -CA$24m |
| Apr 30 2022 | n/a | n/a | -CA$22m |
| Jan 31 2022 | n/a | n/a | -CA$18m |
| Oct 31 2021 | CA$259k | CA$240k | -CA$14m |
| Jul 31 2021 | n/a | n/a | -CA$9m |
| Apr 30 2021 | n/a | n/a | -CA$7m |
| Jan 31 2021 | n/a | n/a | -CA$5m |
| Oct 31 2020 | CA$115k | CA$66k | -CA$5m |
| Jul 31 2020 | n/a | n/a | -CA$4m |
| Apr 30 2020 | n/a | n/a | -CA$2m |
| Jan 31 2020 | n/a | n/a | -CA$4m |
| Oct 31 2019 | CA$238k | CA$204k | -CA$4m |
| Jul 31 2019 | n/a | n/a | -CA$3m |
| Apr 30 2019 | n/a | n/a | -CA$3m |
| Jan 31 2019 | n/a | n/a | -CA$3m |
| Oct 31 2018 | CA$247k | CA$200k | -CA$2m |
| Jul 31 2018 | n/a | n/a | -CA$3m |
| Oct 31 2017 | CA$243k | CA$201k | -CA$4m |
Compensation vs Market: Steve's total compensation ($USD341.52K) is about average for companies of similar size in the German market ($USD401.52K).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
CEO
Steve Saviuk (64 yo)
21.3yrs
Tenure
CA$466,291
Compensation
Mr. Steven Saviuk, also known as Steve, CA, serves as Independent Director at Cluny Capital Corp. since April 15, 2021. Mr. Saviuk serves as Vice Chairman of Valeo Pharma Inc. since January 18, 2021 and it...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman | 21.3yrs | CA$466.29k | 0.18% CA$ 14.2k | |
| Senior VP & Chief Commercial Officer | 1.7yrs | CA$388.21k | 0.020% CA$ 1.5k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Director of Communications & Investor Relations | 3.3yrs | no data | no data | |
| VP of Legal Affairs & Corporate Secretary | no data | no data | 0.41% CA$ 31.4k | |
| Head of Ophthalmology Business Unit | 1.7yrs | no data | no data |
1.7yrs
Average Tenure
Experienced Management: VP2's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman | 21.1yrs | CA$466.29k | 0.18% CA$ 14.2k | |
| Independent Director | less than a year | no data | 0.18% CA$ 13.8k | |
| Chairman of the Board & Chairman of the Advisory Board | 15.3yrs | no data | 16.44% CA$ 1.3m | |
| Independent Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 2yrs | no data | 2.36% CA$ 183.2k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
0.4yrs
Average Tenure
64yo
Average Age
Experienced Board: VP2's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.